Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 645 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Process-level Clear all
Not listed No phase listed Observational

Study of Treatment's Echocardiographic Mechanisms

NCT03913403
View directory record Official record
Conditions
Sepsis
Interventions
ECHO, Blood Draw
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Boston, Massachusetts • The Bronx, New York • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470
View directory record Official record
Conditions
Acute Graft-versus-host Disease
Interventions
Efmarodocokin Alfa
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional

A Randomized Trial: Changing Behavior in Post-Angioplasty Patients

NCT00248846
View directory record Official record
Conditions
Angioplasty Patients
Interventions
Intervention Group
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 110 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 20, 2026, 5:49 AM EDT
Active, not recruiting Phase 2 Interventional

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

NCT04018937
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 13 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Active, not recruiting Phase 2 Interventional

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Cyclophosphamide, Abatacept, Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location

NCT02152696
View directory record Official record
Conditions
Persistent Pregnancy of Unknown Location, Ectopic Pregnancy
Interventions
Methotrexate, Uterine Evacuation, Expectant Management
Drug · Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00701688
View directory record Official record
Conditions
Oral Mucositis, Hematopoietic Stem Cell Transplantation
Interventions
Palifermin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 20, 2026, 5:49 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Early Screen and Treatment for Gestational Diabetes

NCT02377531
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Early glucose screen group, Standard glucose screen group
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,020 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 20, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional

JSP191 Antibody Targeting Conditioning in SCID Patients

NCT02963064
View directory record Official record
Conditions
SCID
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Biological
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
3 Months to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

Prevention of Oral Mucositis Using Photobiomodulation Therapy

NCT04227340
View directory record Official record
Conditions
Oral Mucositis
Interventions
Photobiomodulation Therapy (PBM), Pain and Oral Function Assessment, Parent-Reported Satisfaction Survey
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 20, 2026, 5:49 AM EDT
Active, not recruiting Not applicable Interventional

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

NCT00959140
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
CD3+ T cell depletion
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT00576979
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, etoposide, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, intensity-modulated radiation therapy, tomotherapy
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
7 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

Co-Use of Opioid Medications and Alcohol Prevention Study

NCT05599672
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use
Interventions
Alcohol-targeted Brief Intervention-Medication Therapy Management, Standard medication counseling
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Withdrawn Not applicable Interventional

Feasibility Open Label Study Evaluating The Use Of Process-Instructed Self Neuro-Modulation (PRISM) For Post-Traumatic Stress Disorder

NCT04496557
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit

NCT07173205
View directory record Official record
Conditions
Depression, Cancer, Adolescent, Young Adult, Adult
Interventions
AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
15 Years to 39 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Greenville, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
View directory record Official record
Conditions
ALS
Interventions
AMX0114, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

NCT02206035
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
William R. Drobyski, MD
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Comparing Dry Needling to Manual Therapy for Patients With Mechanical Low Back Pain

NCT02312895
View directory record Official record
Conditions
Low Back Pain
Interventions
Manual therapy, Dry needling, Home Exercise Program
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

NCT01593397
View directory record Official record
Conditions
Obesity
Interventions
Propofol and Fentanyl administration
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5

NCT02582918
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Neoplasms
Interventions
Outreach with patient education and patient navigation services
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
2,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation

NCT03292562
View directory record Official record
Conditions
Apnea of Prematurity, Respiratory Distress Syndrome
Interventions
Discontinue NCPAP after weaning pressures, Discontinue NCPAP without weaning pressures
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 20, 2026, 5:49 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing Home, Office, and Telehealth Induction for Medication Assisted Treatment for Opioid Use Disorder

NCT04664062
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence
Interventions
Medication Assisted Treatment
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 89 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Denver, Colorado • Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Research Evaluating Sleep & Trends for Universal Prevention

NCT04783519
View directory record Official record
Conditions
Insomnia, Alcohol Use, Unspecified, Marijuana Use
Interventions
Brief Behavioral Therapy for Insomnia (BBTI), Brief Alcohol Screening and Intervention for College Students (BASICS)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 24 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 20, 2026, 5:49 AM EDT